• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    6/6/23 9:06:46 AM ET
    $BIAF
    $EVAX
    $HOTH
    $HTGM
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BIAF alert in real time by email

    Gainers

    • Hoth Therapeutics (NASDAQ:HOTH) shares rose 99.5% to $3.75 during Tuesday's pre-market session. The company's market cap stands at $12.3 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) stock increased by 22.15% to $0.15. The market value of their outstanding shares is at $22.3 million.
    • T2 Biosystems (NASDAQ:TTOO) stock increased by 18.14% to $0.08. The market value of their outstanding shares is at $2.0 million.
    • Medigus (NASDAQ:MDGS) stock rose 16.61% to $5.14. The company's market cap stands at $8.4 million.
    • Zura Bio (NASDAQ:ZURA) shares rose 15.55% to $7.5. The company's market cap stands at $238.5 million.
    • PDS Biotechnology (NASDAQ:PDSB) shares increased by 13.16% to $7.39. The market value of their outstanding shares is at $227.7 million.

    Losers

    • HTG Molecular Diagnostics (NASDAQ:HTGM) shares decreased by 41.0% to $0.99 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.1 million.
    • Timber Pharmaceuticals (AMEX:TMBR) shares fell 11.71% to $1.66. The market value of their outstanding shares is at $5.0 million.
    • Pluri (NASDAQ:PLUR) stock declined by 8.59% to $0.73. The company's market cap stands at $30.0 million.
    • bioAffinity Technologies (NASDAQ:BIAF) shares fell 8.07% to $1.71. The company's market cap stands at $14.5 million.
    • INVO Bioscience (NASDAQ:INVO) shares fell 7.95% to $0.18. The market value of their outstanding shares is at $2.5 million.
    • Evaxion Biotech (NASDAQ:EVAX) stock fell 7.85% to $1.41. The company's market cap stands at $37.2 million. As per the news, the Q1 earnings report came out 4 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BIAF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIAF
    $EVAX
    $HOTH
    $HTGM

    CompanyDatePrice TargetRatingAnalyst
    Evaxion A/S
    $EVAX
    2/19/2026$10.00Buy
    Maxim Group
    Zura Bio Limited
    $ZURA
    2/9/2026$15.00Outperform
    Wedbush
    Zura Bio Limited
    $ZURA
    11/4/2024$15.00Outperform
    Leerink Partners
    Zura Bio Limited
    $ZURA
    9/5/2024$5.00Neutral
    H.C. Wainwright
    Zura Bio Limited
    $ZURA
    5/3/2024$26.00Overweight
    Piper Sandler
    Evaxion A/S
    $EVAX
    4/2/2024$8.00Neutral → Buy
    Ladenburg Thalmann
    Evaxion A/S
    $EVAX
    2/12/2024$14.00Buy
    H.C. Wainwright
    Zura Bio Limited
    $ZURA
    10/10/2023$10.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $BIAF
    $EVAX
    $HOTH
    $HTGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 3 filed by new insider Mattsson Andreas Holm

    3/A - Evaxion A/S (0001828253) (Issuer)

    4/10/26 4:20:54 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Davis Kim

    4 - Zura Bio Ltd (0001855644) (Issuer)

    4/2/26 6:00:20 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Nistala Kiran

    4 - Zura Bio Ltd (0001855644) (Issuer)

    4/2/26 6:00:23 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIAF
    $EVAX
    $HOTH
    $HTGM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ai Biotechnology Llc bought $12,500,000 worth of Class A Ordinary Shares (2,000,000 units at $6.25) (SEC Form 4)

    4 - Zura Bio Ltd (0001855644) (Issuer)

    3/2/26 5:55:03 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Manieu Alexandre Weinstein was granted 10,250 shares, exercised 1,002,169 shares at a strike of $0.00 and bought $2,086,956 worth of shares (452,702 units at $4.61) (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    11/20/25 11:35:50 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Manieu Alexandre Weinstein bought $4,500,001 worth of shares (976,139 units at $4.61) and disposed of 976,139 shares (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    7/1/25 4:00:11 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIAF
    $EVAX
    $HOTH
    $HTGM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial

    New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune responseThe results reinforce that Evaxion's pioneering AI platform, AI-Immunology™ accurately identifies and selects the most relevant vaccine targetsData will be presented at the American Association for Cancer Research (AACR) Annual Meeting COPENHAGEN, Denmark, April 17, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new data demonstrating that AI-Immunology™ identifies and selects the most therapeutically relevant vaccine targets. The

    4/17/26 3:10:00 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New data demonstrates the unique scalability of Evaxion's AI-Immunology™ platform in glioblastoma

    Data analysis conducted in collaboration with a leading academic medical center shows that AI‑Immunology™ enables vaccine design also for the deadly brain cancer, glioblastomaUniquely, the platform can identify a novel source of targets to include in glioblastoma cancer vaccines, potentially enhancing their efficacyData will be presented at the American Association for Cancer Research (AACR) Annual Meeting COPENHAGEN, Denmark, April 17, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new data demonstrating the platform's ability to also potentially develop vaccines for glioblastom

    4/17/26 3:00:00 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion concludes Annual General Meeting

    COPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, held its Annual General Meeting today at the company's offices. The 2025 Annual Report was approved and the Board of Directors' proposals passed. Marianne Søgaard, Lars Holtug, Lars Aage Staal Wegner and Roberto Prego Pineda were re-elected to the Board of Directors. Jens Bitsch Nørhave was elected to the Board of Directors. Minutes from the meeting can be found on our website. Contact information Evaxion A/S Mads Kronborg Vice President, Investor Relations & Communication +45 53 54 82 96 [email protected] Abo

    4/16/26 11:30:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIAF
    $EVAX
    $HOTH
    $HTGM
    SEC Filings

    View All

    Zura Bio Limited filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Zura Bio Ltd (0001855644) (Filer)

    4/23/26 4:50:58 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Pluri Inc.

    DEFA14A - Pluri Inc. (0001158780) (Filer)

    4/23/26 4:02:46 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by Pluri Inc.

    DEF 14A - Pluri Inc. (0001158780) (Filer)

    4/23/26 4:02:29 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIAF
    $EVAX
    $HOTH
    $HTGM
    Financials

    Live finance-specific insights

    View All

    PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement

    Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs Conference Call and Webcast Today at 8:00 am Eastern Time PRINCETON, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter and year ended December 31, 2025. "The fourth quarter capped a year of important progress for PDS Biotech, marked by meaningful advances across our clinical p

    3/30/26 7:00:00 AM ET
    $PDSB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results

    PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call and webcast to report financial results for the quarter and year ended December 31, 2025, and will provide a clinical programs and corporate update, on Monday, March 30, 2026 at 8:00 am Eastern Time. Conference Call DetailsDate: March 30, 2026Time: 8:00 a.m. Eastern TimeDial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International)Conference I.D.: 13759288Webcast: Click HereCallMe™: Click H

    3/24/26 4:05:00 PM ET
    $PDSB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evaxion plans to file 2025 annual report later today

    COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will slightly delay the filing and publication of its 2025 annual report, planned before opening of Nasdaq CM today, due to unforeseen technical issues with external vendors.   The report has been finalized as planned and will be filed and published as soon as possible. The technical issues relate to regulatory filing demands and have nothing to do with the report itself.  As a consequence of the technical delay, the conference call and webcast planned for today will be moved to tomorrow: Friday March 6 at 8.30 E

    3/5/26 8:02:13 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIAF
    $EVAX
    $HOTH
    $HTGM
    Leadership Updates

    Live Leadership Updates

    View All

    Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointments of Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. As part of this transition, Neil Graham, M.B.B.S., M.D., M.P.H., will step down from the Board effective the same date. "Mark and Ajay are accomplished immunology executives who have successfully guided innovative biologics from early development through approval and commercialization on a

    2/23/26 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board

    Advisory Board provides independent guidance on strategic priorities, including growing adoption of the Company's noninvasive CyPath® Lung diagnostic test bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced new appointments to its Medical and Scientific Advisory Board, welcoming David Ost, MD, MPH, University of Texas MD Anderson Cancer Center, Daniel Sterman, MD, New York University Langone Medical Center, and J. Scott Ferguson, MD, University of Wisconsin School of Medicine and Public Health, to its panel of recognized leaders in the field. The appointments reflect a planned expans

    2/9/26 8:00:00 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Sandeep Kulkarni, M.D. as Chief Executive Officer (CEO), effective January 21, 2026. Dr. Kulkarni will also continue serving as a Director of Zura. Dr. Kulkarni succeeds Kim Davis, J.D., who has served as Interim CEO since October 2025 following the commencement of a medical leave of absence by CEO Robert Lisicki. Mr. Lisicki is resigning as CEO and as a Director, effective as of January 21, 2026. Ms.

    1/21/26 8:50:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIAF
    $EVAX
    $HOTH
    $HTGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 5:52:59 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 5:06:21 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Zura Bio Limited

    SC 13G - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 4:47:14 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIAF
    $EVAX
    $HOTH
    $HTGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Evaxion Biotech with a new price target

    Maxim Group initiated coverage of Evaxion Biotech with a rating of Buy and set a new price target of $10.00

    2/19/26 8:24:06 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wedbush initiated coverage on Zura Bio Limited with a new price target

    Wedbush initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00

    2/9/26 6:54:14 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Leerink Partners initiated coverage on Zura Bio Limited with a new price target

    Leerink Partners initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00

    11/4/24 7:45:03 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care